NCT01575548: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 1020 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01575548 |
|---|---|
| Title | Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 8, 2012 |
| Completion date | July 17, 2018 |
| Required reporting date | July 17, 2019, midnight |
| Actual reporting date | May 2, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 1020 |